Overview

Study to Evaluate the Safety and Tolerability of EP0042

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ellipses Pharma